Sana Biotechnology (SANA) announced the appointments of two senior leaders to its research and development organization, Douglas Williams as president of research and development, and Gary Meininger as chief medical officer. In a planned transition, Sunil Agarwal, chief medical officer, will leave the company after helping onboard these new executives. Williams has over three decades of experience and most recently he was CEO of Codiak BioSciences (CDAK). Meininger was previously at Vertex (VRTX) as senior VP, head of clinical development for Vertex Cell and Genetic Therapies, or VCGT, overseeing all aspects of clinical development for VCGT.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SANA:
- Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization
- Sana Biotechnology price target lowered to $11 from $13 at BofA
- Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
- Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting
- Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference